2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1407

Disease Activity Trackers to Support Treat to Target Strategies: A Needs Assessment Survey
Abstract Number: 1408

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Patient Reported Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Abstract Number: 1409

Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Abstract Number: 1410

Is the Self-Assessment of Disease Activity (auto-DAS28) By Patients a Feasible and Acceptable Measure over the Long Term in Rheumatoid Arthritis (RA)? Three-Year Follow-up of a Nurse-Led Program in 771 Patients with Established RA
Abstract Number: 1411

An Electronic MDHAQ (multidimensional health assessment questionnaire) Beyond an Electronic RAPID (routine assessment of patient index data): 21.3% of Rheumatoid Arthritis Patients Identified As Having Secondary Fibromyalgia Versus 3.5% By Clinicians
Abstract Number: 1412

Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model
Abstract Number: 1413

Establishing Clinical Severity for Patient Reported Outcomes Measurement Information System Measures in Adult Patients with Rheumatic Diseases
Abstract Number: 1414

Access to an Active, Interactive Self-Assessment e-Health Platform Improves Patient-Physician Communication in Rheumatoid Arthritis: Results of a Randomized Controlled Trial Including 320 Patients over 1 Year
Abstract Number: 1415

Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Abstract Number: 1416

Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic
Abstract Number: 1417

Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission
Abstract Number: 1418

Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!
Abstract Number: 1419

Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients
Abstract Number: 1420

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Abstract Number: 1421

Responsiveness of Lupus Impact Tracker Among Chinese Patients with Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].